N-Amylpropargylamin | 22774-62-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Amylpropargylamin
• 英文别名: N-n-Pentyl-2-propinylamin；Propargylpentylamin；N-(1-Pentyl) propargylamine；N-prop-2-ynylpentan-1-amine
• CAS: 22774-62-5
• 化学式: C₈H₁₅N
• mdl: MFCD07411967
• 分子量: 125.214
• InChiKey: PZDKPUHSLZLJNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-Amylpropargylamin 在 potassium tert-butylate 作用下， 以 叔丁醇 为溶剂， 反应 0.33h， 生成 N-Allyliden-n-pentylamin
  参考文献：
  名称：

  仲炔丙基胺的质子重排

  摘要：

  DOI：

  10.1016/0040-4020(73)80246-7
• 作为产物：
  描述：

  炔丙基苯磺酸 、 1-氨基戊烷 以 丙酮 为溶剂， 生成 N-Amylpropargylamin
  参考文献：
  名称：

  Vizgert,R.V. et al., Journal of Organic Chemistry USSR (English Translation), 1969, vol. 5, p. 914 - 919

  摘要：

  DOI：

文献信息

• [EN] POLYSUBSTITUTED 2-AMINOIMIDAZOLES FOR CONTROLLING BIOFILMS AND PROCESS FOR THEIR PRODUCTION<br/>[FR] 2-AMINOIMIDAZOLES POLYSUBSTITUÉS DESTINÉS À LA LUTTE CONTRE LA FORMATION DE BIOFILMS ET LEUR PROCÉDÉ DE PRODUCTION
  申请人：UNIV LEUVEN KATH

  公开号：WO2012041934A1

  公开（公告）日：2012-04-05

  The present invention relates to compounds, compositions and methods for controlling and/or preventing biofilms and bacterial infections, being polysubstituted 2-amino-imidazoles with the structural formula (I). wherein R1 is H, an aliphatic group or a cycloaliphatic group; R2 is H, an aliphatic group or a cycloaliphatic group; R3 is an aliphatic group, a cycloaliphatic group, an aromatic group or a heterocyclic group; and R4 is an aliphatic group, a cycloaliphatic group, an aromatic group or a heterocyclic group; and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomeric forms or polymorphic substances thereof.

  本发明涉及化合物、组合物和方法，用于控制和/或预防生物膜和细菌感染，其中为具有结构式（I）的多取代2-氨基咪唑。其中R1为H、脂肪基或环脂肪基；R2为H、脂肪基或环脂肪基；R3为脂肪基、环脂肪基、芳香族基或杂环基；R4为脂肪基、环脂肪基、芳香族基或杂环基；以及其药用可接受的盐、水合物、溶剂合物、前药、立体异构体形式或多形物质。
• 4-Aminobut-2-yne carboxylic acid derivatives and their use as antimicrobial agents
  申请人：Ciba Specialty Chemicals Holding Inc.

  公开号：EP1215198A1

  公开（公告）日：2002-06-19

  There are described 4-aminobut-2-ynecarboxylic acid derivatives of formula wherein R1 and R2are each independently of the other hydrogen, C1-C20alkyl; C3-C12cycloalkyl; unsubstituted or C1-C5alkyl-, C3-C12cycloalkyl-, C1-C5alkoxy-, C3-C12cycloalkoxy-, halo-, oxo-, carboxy-, carboxy-C1-C7alkyl ester-, carboxy-C3-C12cycloalkyl ester-, cyano-, trifluoromethyl-, pentafluoroethyl-, amino-, N,N-mono- or di-C1-C20alkylamino- or nitro-substituted phenyl, phenyl-C1-C5alkyl, naphthyl and naphthyl-C1-C5alkyl; and R3is C1-C20alkyl; C3-C12cycloalkyl. The compounds exhibit a pronounced activity against gram-positive and gram-negative bacteria, and also against yeasts and moulds.

  这里描述了公式为R1和R2分别独立地为氢、C1-C20烷基、C3-C12环烷基、未取代或C1-C5烷基、C3-C12环烷基、C1-C5烷氧基、C3-C12环烷氧基、卤素、氧代、羧基、羧基-C1-C7烷基酯、羧基-C3-C12环烷基酯、氰基、三氟甲基、五氟乙基、氨基、N，N-单或双-C1-C20烷基氨基或硝基取代的苯、苯-C1-C5烷基、萘和萘-C1-C5烷基的4-氨基丁-2-炔羧酸衍生物，其中R3为C1-C20烷基、C3-C12环烷基。这些化合物对革兰氏阳性和阴性细菌以及酵母菌和霉菌具有显著的活性。
• 4-aminobut-2-ynecarboxylic acid derivatives
  申请人：——

  公开号：US20020115881A1

  公开（公告）日：2002-08-22

  There are described 4-aminobut-2-ynecarboxylic acid derivatives of formula 1 wherein R 1 and R 2 are each independently of the other hydrogen, C 1 -C 20 alkyl; C 3 -C 12 cycloalkyl; un-substituted or C 1 -C 5 alkyl-, C 3 -C 12 cycloalkyl-, C 1 -C 5 alkoxy-, C 3 -C 12 cycloalkoxy-, halo-, oxo-, carboxy-, carboxy-C 1 -C 7 alkyl ester-, carboxy-C 3 -C 12 cycloalkyl ester-, cyano-, trifluoromethyl-, pentafluoroethyl-, amino-, N,N-mono- or di-C 1 -C 20 alkylamino- or nitro-substituted phenyl, phenyl-C 1 -C 5 alkyl, naphthyl and naphthyl-C 1 -C 5 alkyl; and R 3 is C 1 -C 20 alkyl; C 3 -C 12 cycloalkyl. The compounds exhibit a pronounced activity against gram-positive and gram-negative bacteria, and also against yeasts and moulds.

  描述了式1的4-氨基丁-2-炔羧酸衍生物，其中R1和R2各自独立地为氢、C1-C20烷基、C3-C12环烷基、未取代或C1-C5烷基、C3-C12环烷基、C1-C5烷氧基、C3-C12环烷氧基、卤素、氧代、羧基、羧基-C1-C7烷基酯基、羧基-C3-C12环烷基酯基、氰基、三氟甲基、五氟乙基、氨基、N,N-一或二-C1-C20烷基氨基或硝基取代的苯基、苯基-C1-C5烷基、萘基和萘基-C1-C5烷基；R3为C1-C20烷基、C3-C12环烷基。这些化合物对革兰氏阳性和阴性细菌、酵母菌和霉菌具有显著的活性。
• FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：Seko Takuya

  公开号：US20080261947A1

  公开（公告）日：2008-10-23

  Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.

  式（I）所表示的融合吡嗪衍生物或其药学上可接受的盐（其中每个符号的含义如规范中所定义）。由于抑制了聚(ADP-核糖)聚合酶，式（I）所表示的化合物可用作预防和/或治疗各种缺血性疾病（在大脑、脊髓、心脏、消化道、骨骼肌、视网膜等部位），炎症性疾病（炎症性肠病、多发性硬化症、关节炎等），神经退行性疾病（锥体外系障碍、阿尔茨海默病、肌萎缩症、腰椎管狭窄等），糖尿病、休克、头部创伤、肾功能衰竭、高痛感等。此外，这些化合物还可用作抗逆转录病毒剂（HIV等）、治疗癌症的增敏剂和免疫抑制剂。
• Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP2281818A1

  公开（公告）日：2011-02-09

  Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.

  式 (I) 所代表的融合哒嗪衍生物或其药学上可接受的盐（其中各符号的含义如说明书中所定义）。 由于能抑制多（ADP-核糖）聚合酶，式（I）代表的化合物可作为各种缺血性疾病（脑、脊髓、心脏、消化道、骨骼肌、视网膜等）、炎症性疾病（炎症性肠病）的预防和/或治疗药物。炎症性疾病（炎症性肠病、多发性脑硬化症、关节炎等）、神经退行性疾病（锥体外系障碍、阿尔茨海默病、肌肉萎缩症、腰椎管狭窄症等）、糖尿病、休克、头部创伤、肾功能衰竭、痛觉减退等。此外，这些化合物还可用作抗逆转录病毒（HIV 等）的药物、治疗癌症的增敏剂和免疫抑制剂。